Linsitinib (formerly known as OSI-906) is an oral inhibitor of both insulin-related growth factor receptor 1 (IGF-1R) and the insulin receptor (IR).
Manufacturer: OSI Pharmaceuticals, a subsidiary of Astellas.
Description from NCI Drug Dictionary: An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGFR-1 stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis.
New Trial for Wildtype GIST
A Phase 2 Study of OSI-906 (linsitinib) in Pediatric and Adult Patients With Wild Type Gastrointestinal Stromal Tumors (NCT 01560260) opened in March 2012. Patients age 15 and above with wildtype GIST (no mutations in the KIT or PDGFRA genes) may be eligible, including patients with Carney Triad and those with Carney-Stratakis dyad (GIST + paraganglioma). Link on the trial title above for details. Trial sites include California, Maryland, Massachusetts, Michigaan, Oregon, and Pennsylvania.
Past Trials (Phase 1)
Phase 1 Study of Continuous OSI-906 Dosing (NCT00514007)
Phase 1 Study of Intermittent OSI-906 Dosing (NCT00514306)